Introduction
Glycogen synthase kinase-3 (GSK3α/β) is a constitutively active, ubiquitous serine/threonine kinase abundant in the central nervous system (CNS, (Woodgett, 1990) ). It phosphorylates a broad range of substrates including β-catenin (Rubinfeld et al, 1996) , the immediate early gene c-Jun (Boyle et al., 1991) , the adaptor protein for trophic factor signalling, IRS-1 (Eldar-Finkelman and Krebs, 1997), the cytoskeletal protein tau (Hong et al., 1997; Takashima et al., 1993) and glycogen synthase (Beurel and Jope, 2006) . Its regulation is similarly complex, being activated, by several factors, including intracellular calcium (Hartigan and Johnson, 1999) , the tyrosine kinases ZAK1 (Kim et al., 1999) and Fyn (Lesort et al., 1999) (as reviewed by Forde and Dale (2007) ). Its inhibition is mediated primarily by PI3K-Akt via serine phosphorylation (Ueki et al., 1998) or by Wnt signaling (Siegfried et al., 1992) .
Although the general consensus is that aberrant over-expression of GSK3 promotes cell death (Carmichael et al., 2002; Jin et al., 2005; Maggirwar et al., 1999; Pap and Cooper, 1998; Tong et al., 2001 ) and inhibits cell proliferation (Sato et al., 2004; Tseng et al., 2006) , emerging studies indicate that its relatively high constitutive activity is critical for neuron function (Hoeflich et al., 2000; Ougolkov et al., 2007; Takada et al., 2004) . Two recent studies in transgenic mice supported this hypothesis that constitutive GSK3 is important for neuron viability (Gomez-Sintes et al., 2007) and for long-term depression (LTD), an electrophysiological measurement related to memory consolidation (Peineau et al., 2007) .
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